May 2018: Does pulmonary rehabilitation need more PR?
By BMJ Group
In this month’s podcast, James Cave (DTB Editor-in-Chief) and David Phizackerley (DTB Deputy Editor) discuss the evidence for pulmonary rehabilitation for COPD and highlight the need for more publicity for its benefits. Read the editorial here: http://dtb.bmj.com/content/56/5/49. The editors also review the evidence for safinamide for Parkinson’s disease (http://dtb.bmj.com/content/56/5/54), and discuss the use of bezlotoxumab, a monoclonal antibody licensed for the prevention of recurrence of Clostridium difficile infection in adults who are at high risk of recurrence (http://dtb.bmj.com/content/56/5/57).